Claims

1. A method for reducing antennary fucosylation of complex N-glycans in a glycoprotein, wherein the method comprises a step of overexpressing said glycoprotein together with β-galactoside α-2,6-sialyltransferase 1 (ST6Gal1) and/or α-2,3-sialyltransferase 4 (ST3Gal4) and wherein the glycoprotein is recombinantly expressed in a cell line that is derived from human primary amniocytes comprising at least one nucleic acid encoding the gene products of the adenoviral E1 and pIX regions.

2. The method of claim 1, wherein the glycoprotein is characterized by a significantly reduced antennary fucosylation of complex N-glycans as compared to the same recombinant glycoprotein expressed without overexpression of ST6Gal1 and/or ST3Gal4, wherein at least 80% of the complex N-glycan antennae of the recombinantly expressed glycoprotein are not fucosylated.

3. The method of any one of claims 1 to 2, wherein the glycoprotein is selected from the group consisting of α1-antitrypsin (AAT), hepatocyte growth factor (HGF), Factor VII (FVII), Factor VIII (FVIII), Factor IX (FIX), von Willebrand-Factor (vWF), alkaline phosphatase, and C1 esterase inhibitor (C1-inhibitor; C1 Inh).

4. The method of any one of claims 1 to 3, wherein the glycoprotein is a mammalian, preferably a human glycoprotein.

5. The method of any one of claims 1 to 4, wherein
   (i) β-galactoside α-2,3-sialyltransferase 1 (ST3Gal1) is not overexpressed together with the glycoprotein, and/or
   (ii) the expression of α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (GnTIVa), α-1,3-mannosyl-glycoprotein 4-β-

N-acetylglucosaminyltransferase B (GnTIVb), and α-1,6-mannosylglycoprotein 6-β-N-acetylglucosaminyltransferase A (GnTV) is not reduced.

6. A method for the expression of a recombinant glycoprotein, comprising the steps of:
   (a) providing a cell line,
   (b) expressing the recombinant glycoprotein in said cell line;
   (c) isolating the recombinant glycoprotein from the cells or the cell culture supernatant,

   wherein the cell line is genetically modified to overexpress β-galactoside α-2,6-sialyltransferase 1 (ST6Gal1) and/or α-2,3-sialyltransferase 4 (ST3Gal4), and wherein the cell line is derived from human primary amniocytes comprising at least one nucleic acid encoding the gene products of the adenoviral E1 and pIX regions.

7. The method of claim 6, wherein the recombinant glycoprotein has complex N-glycans and the antennary fucosylation of the complex N-glycans is reduced, so that at least 80% of the complex N-glycan antennae of the recombinant glycoprotein are not fucosylated.

8. The method of claim 6, wherein the glycoprotein is selected from the group consisting of α1-antitrypsin (AAT), hepatocyte growth factor (HGF), Factor VII (FVII), Factor VIII (FVIII), Factor IX (FIX), von Willebrand-Factor (vWF), alkaline phosphatase, and C1 esterase inhibitor (C1-inhibitor; C1 Inh).

9. The method of claim 6, wherein the cell line comprises endogenous gene(s) encoding ST6Gal1 and/or ST3Gal4, and further has at least one genetic element, selected from the group consisting of a promoter, an enhancing element, and a

stabilizing element inserted into the genome in one or more position(s) suitable to cause overexpression of ST6Gal1 and/or ST3Gal4.

10. The method of claim 6, wherein the cell line comprises exogenous nucleic acid(s) encoding ST6Gal1 and/or ST3Gal4.

11. The method of claim 6, wherein the cell line is derived from CAP cells that are permanent amniocytic cell lines comprising a nucleic acid encoding the gene products of the adenovirus, particularly adenovirus type 5 (Ad5), E1A and E1B region.

12. The method of claim 6, wherein the cell line is not genetically modified to
    (i) overexpress β-galactoside α-2,3-sialyltransferase 1 (ST3Gal1), and/or
    (ii) reduce the expression of α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (GnTIVa), α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase B (GnTIVb), and α-1,6-mannosylglycoprotein 6-β-N-acetylglucosaminyltransferase A (GnTV).